2-乙基-4-甲基-嘧啶 | 75074-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-乙基-4-甲基-嘧啶
• 英文名称: 2-ethyl-4-methyl-pyrimidine
• 英文别名: 2-Aethyl-4-methyl-pyrimidin；2-Ethyl-4-methylpyrimidine
• CAS: 75074-97-4
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: XNWDWIGATDEYAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-乙基-4-甲基-嘧啶
  参考文献：
  名称：

  Pinner, Chemische Berichte, 1889, vol. 22, p. 1610

  摘要：

  DOI：

文献信息

• [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011025774A1

  公开（公告）日：2011-03-03

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• PDE4 INHIBITOR
  申请人：SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.

  公开号：US20190177318A1

  公开（公告）日：2019-06-13

  Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

  提供了一种PDE4抑制剂及其在制备用于治疗与PDE4相关疾病的药物中的用途。具体披露了如公式（I）所示的化合物及其药用可接受的盐。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
  申请人：Addex Pharma S.A.

  公开号：US20140349994A1

  公开（公告）日：2014-11-27

  The present invention relates to novel compounds of Formula (I), wherein M and R 1 are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式（I）的新化合物，其中M和R1如式（I）中所定义；该发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，对于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病具有用处。该发明还涉及制药组合物以及利用这类化合物制造药物的用途，以及利用这类化合物预防和治疗涉及mGluR4的疾病的用途。
• Organic Compounds
  申请人：Caravatti Giorgio

  公开号：US20090163469A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。